We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bionano Genomics Inc | NASDAQ:BNGO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0107 | 1.13% | 0.96 | 0.90 | 1.12 | 1.02 | 0.9301 | 0.9763 | 980,221 | 05:00:10 |
Delaware
|
001-38613
|
26-1756290
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
9540 Towne Centre Drive, Suite 100
San Diego, California
|
92121
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
Common Stock, $0.0001 par value per share
|
BNGO
|
The Nasdaq Stock Market LLC
|
||
Warrants to purchase Common Stock
|
BNGOW
|
The Nasdaq Stock Market LLC
|
Item 9.01 |
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit No.
|
Description
|
|
Consent of Tanner LLC, independent registered public accounting firm.
|
||
Audited financial statements of Lineagen as of and for the years ended December 31, 2019 and 2018, and unaudited interim financial statements of Lineagen as of June 30, 2020 and for the six
months ended June 30, 2020 and 2019.
|
||
Unaudited pro forma consolidated combined balance sheet for the Company and Lineagen as of June 30, 2020 and unaudited pro forma consolidated combined statements of operations for the Company
and Lineagen for the year ended December 31, 2019 and for the six months ended June 30, 2020.
|
Bionano Genomics, Inc.
|
||
Date: November 3, 2020
|
By:
|
/s/ R. Erik Holmlin, Ph.D.
|
R. Erik Holmlin, Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
|
1 Year Bionano Genomics Chart |
1 Month Bionano Genomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions